How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview. 

The new gene therapy candidate is now one step closer to being approved by the FDA. 

In a study, CT-FFR was shown to reduce the need for invasive tests to measure coronary artery blockage from 74.5% to 25.5%.

Radiologists with Massachusetts General Hospital found that the selective use of cardiac CT and AI-based CAD evaluations could make a significant impact on patient care. 

ACC.24, the American College of Cardiology's annual meeting in Atlanta, featured the latest in cardiovascular research and technologies. Representatives from Cardiovascular Business were there in person to take in the excitement. 

The Dual Energy THERMOCOOL SMARTTOUCH SF Catheter is the first dual energy pulsed field (PF) ablation / radiofrequency (RF) ablation catheter integrated with a PF and RF ablation index.

An independent heart team blinded to ICA results was able to deliver helpful guidance for CABG procedures for 99.1% of patients using just CCTA and FFR_CT alone. This approach is safe and feasible, researchers wrote, and the next step is to gather additional data. 

The PREVENT study, presented at ACC.24, examined more than 1,600 patients with high-risk plaques treated with either preventive PCI or medical therapy alone. Outcomes were much better for the PCI group after two years, but the findings may lead to more questions than answers.